CYTO: Auris Medical P/S multiplikatori

Altamira Therapeutics (CYTO) brendining ramzi va logotipi

Miya va eshitish tizimiga yo'naltirilgan dori vositalarini yetkazib berishga bo'lgan talab Altamira Therapeutics (CYTO) kompaniyasida ixtisoslashgan ekspertlarni jalb qilishni rag'batlantirmoqda. Sotuvlarga nisbatan narx ko'rsatkichi tebranishlarni namoyon etmoqda, 4.40 esa ushbu parametrning qiymatini ko'rsatadi. O'sish istiqbollari saratonni davolash bo'yicha OligoPhore patentlariga asoslangan, ammo mahsulotlarning sekin joriy etilishi va burun orqali yuboriladigan vositalar sohasidagi raqobat biznesning himoya imkoniyatlarini cheklamoqda.

Altamira Therapeutics - CYTO Kapitalizatsiyaning daromadga nisbati (davr: 04.07.2022 - 06.11.2023)

Altamira Therapeutics (CYTO) kompaniyasi koʻrsatkichlari kesimi va tahlili

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Narxlar dinamikasi grafigi altamiratherapeutics.com|CYTO - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi haqida ma'lumot:
Bozor kapitallashuvi Auris Medical|CYTO - Kompaniyaning to‘liq qiymati
- balans bo'yicha xususiy kapital ma'lumotlari:
Bitta aksiya uchun sof aktivlar Altamira Therapeutics|CYTO - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga multiplikatori altamiratherapeutics.com|CYTO - Kompaniyaning umumiy aktivlari
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Altamira Therapeutics|CYTO - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati altamiratherapeutics.com|CYTO - Kompaniyaning jamlangan qarzlari|Sof aktivlarga qarzlar Auris Medical|CYTO - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli kredit va qarzlari Altamira Therapeutics|Tezkor likvidlik koeffitsiyenti altamiratherapeutics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
CYTO - Sof daromad|Kutilayotgan sof daromad Altamira Therapeutics|CYTO - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati altamiratherapeutics.com|CYTO - PEG multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Auris Medical|CYTO - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Altamira Therapeutics|CYTO - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi altamiratherapeutics.com|CYTO - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Altamira Therapeutics
- sotishdan tushum va biznes daromadlari ko'rsatkichlari:
CYTO - Kompaniya daromadi|Kompaniyaning kutilayotgan daromadi altamiratherapeutics.com|CYTO - P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Auris Medical
Kompaniyaning umumiy tahlili:CYTO, Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. brend mahsuloti

P/S koeffitsienti biznesning generatsiya qilingan daromad birligi bo'yicha bozor qiymatini belgilaydi va aktiv uchun haqiqiy savdolarga nisbatan to'langan premiumni baholash imkonini beradi. Narxning savdoga nisbati dinamikasini tahlil qilish orqali investor haddan tashqari qimmat baholangan aktivni sotib olishdan qochish uchun Altamira Therapeutics (CYTO) kompaniyasining baholangan qiymatini uning ESG ga yo'naltirilgan RNA terapiyasi ishlanmalarining samaradorligi va klinik jarayonlarining shaffofligi bilan solishtiradi.

Altamira Therapeutics raqobatchilari

HLN (haleon.com) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori KVUE (Kenvue)|P/S multiplikatori Verona Pharma PLC VRNA|MENS - Narxning daromadga nisbati|LGND: Narxning daromadga nisbati|AMRX (Amneal Pharmaceuticals) - Kapitalizatsiyaning daromadga nisbati|PRGO: Kapitalizatsiyaning sotish hajmiga nisbati|ALVO (Alvotech SA) - P/S multiplikatori|P/S multiplikatori Liquidia Corp|Narxning daromadga nisbati Galapagos Genomics (GLPG)|Kapitalizatsiyaning daromadga nisbati ANI Pharmaceuticals Corp ANIP|P/S multiplikatori MNKD (MannKind Corporation)|Narx/daromad koeffitsiyenti amphastar.com (AMPH)|PCRX - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S multiplikatori|Aquestive Corp (AQST) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati SCPH|TECX: Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati TNXP (Tonix Pharmaceuticals Holding Corp.)|Kapitalizatsiyaning sotish hajmiga nisbati SXTC|P/S multiplikatori EPRX (Eupraxia Pharmaceuticals Inc.)|Bozor kapitallashuvining daromadga nisbati BHST|eXoZymes Inc - P/S multiplikatori|Sotuvga nisbatan narx Oramed Pharmaceuticals|enterabio.com (ENTX) - Narxning daromadga nisbati|MindWalk Holdings, Inc. - Bozor kapitallashuvining daromadga nisbati|ABVC (ABVC BioPharma Inc) - P/S multiplikatori|P/S multiplikatori Cumberland Corp|Narxning daromadga nisbati Quantum BioPharma Ltd (QNTM)|FGEN: Narxning sotuvga nisbati|P/S multiplikatori TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Sotuvga nisbatan narx|SNYR: Kapitalizatsiyaning daromadga nisbati|RLYB - P/S multiplikatori|LEXX (lexariabioscience.com) - Kapitalizatsiyaning daromadga nisbati|PULM: Kapitalizatsiyaning sotish hajmiga nisbati|PTHL (Pheton Holdings Limited) - P/S multiplikatori|Aptorum (APM) - Narx/daromad koeffitsiyenti|P/S multiplikatori LYRA|Kapitalizatsiyaning daromadga nisbati Impact BioMedical, Inc. IBO|Narxning daromadga nisbati TNF Pharmaceuticals, Inc. TNFA|Narx/daromad koeffitsiyenti cbdMD Inc. (YCBD)|PainReform - P/S multiplikatori|Lipella Pharmaceuticals Inc (LIPO) - Kapitalizatsiyaning daromadga nisbati|OPTN (Optinose) - Kapitalizatsiyaning daromadga nisbati|Sotuvga nisbatan narx Pieris Pharma (PIRS)|Kapitalizatsiyaning daromadga nisbati PROC|PTPI (petrospharma.com) - Kapitalizatsiyaning sotish hajmiga nisbati|Narxning daromadga nisbati Qilian International Holding (QLI)|SLRN - Sotuvga nisbatan narx|Narxning daromadga nisbati TFF Pharma TFFP